Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Inhibrx, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO , NOV. 14, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025. FOLLOWING THE COMPLETION OF THE SALE OF INBRX-101 (THE "101 TRANSACTION") BY INHIBRX, INC. (THE "FORMER PARENT") TO SANOFI S.A.

INHIBRX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO , NOV. 4, 2025 /PRNEWSWIRE/ --INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY WITH A PIPELINE OF NOVEL BIOLOGIC THERAPEUTIC CANDIDATES, TODAY ANNOUNCED IT WILL BE PRESENTING AT THE FOLLOWING UPCOMING SCIENTIFIC CONFERENCES: 21ST ANNUAL INDUSTRY/ACADEMIA PRECISION ONCOLOGY & RADMED SYMPOSIUM NOVEMBER 5 TH, 2025  LA JOLLA, CALIFORNIA TITLE: DR5 AGONIST CLINICAL DATA IN CHONDROSARCOMA, COLORECTAL CANCER AND EWINGS SARCOMA FORMAT: PRESENTATION PRESENTERS: JOSEP GARCIA, PHD, EXECUTIVE VICE PRESIDENT, CHIEF CLINICAL DEVELOPMENT OFFICER, INHIBRX; KATELYN WILLIS, PHD, DIRECTOR, BIOTHERAPEUTICS, INHIBRX DATE: WEDNESDAY, NOVEMBER 5 TH, 2025 TIME: 4:45 PM EASTERN STANDARD TIME LOCATION:  THE ALEXANDRIA AT TORREY PINES, LA JOLLA, CALIFORNIA CONNECTIVE TISSUE ONCOLOGY SOCIETY (CTOS) 2025 ANNUAL MEETING NOVEMBER 12 TH  15TH, 2025  BOCA RATON, FLORIDA TITLE:THE TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST OZEKIBART (INBRX-109) IN CONVENTIONAL CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY LEAD AUTHOR:ROBIN L. JONES, MD  MEDICAL ONCOLOGY, THE ROYAL MARSDEN AND INSTITUTE OF CANCER RESEARCH FORMAT: PRESENTATION DATE:FRIDAY, NOVEMBER 14TH, 2025 TIME: 8:30 AM  10:00 AM EASTERN STANDARD TIME LOCATION: THE BOCA RATON, BOCA RATON, FLORIDA SOCIETY FOR NEUROONCOLOGY (SNO) 2025 ANNUAL MEETING NOVEMBER 19 TH  23RD, 2025  HONOLULU, HAWAII TITLE:THE TETRAVALENT DEATH RECEPTOR 5 (DR5) AGONIST OZEKIBART (INBRX-109) EXHIBITS ANTI-TUMOR ACTIVITY IN GBM MODELS AS A MONOTHERAPY AND IN COMBINATION WITH TMZ FORMAT:POSTER PRESENTATION DATE: SATURDAY, NOVEMBER 22 ND, 2025 TIME: 4:45 PM  6:00 PM EASTERN STANDARD TIME LOCATION: HAWAII CONVENTION CENTER, HONOLULU, HAWAII; KAMEHAMEHA EXHIBIT HALL II & III THE PRESENTATION AND POSTER WILL BE ACCESSIBLE THROUGH A LINK ON THE INVESTORS' SECTION OF INHIBRX'S WEBSITE AT HTTPS://INHIBRXBIOSCIENCES.INVESTORROOM.COM/EVENTS-AND-PRESENTATIONS UPON COMMENCEM

INHIBRX ANNOUNCES PARTICIPATION IN UPCOMING SCIENTIFIC CONFERENCES

OZEKIBART MEETS ITS PRIMARY ENDPOINT IN CHONDROSARCOMA, DEMONSTRATING A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN MEDIAN PROGRESSION-FREE SURVIVAL COMPARED TO PLACEBO KEY SECONDARY ENDPOINTS REINFORCE THE PRIMARY BENEFIT,DEMONSTRATING MEANINGFUL IMPROVEMENTS IN DISEASE CONTROL AND PATIENT QUALITY OF LIFE INHIBRX PLANS TO FILE A BLA IN Q2 OF 2026 INTERIM DATA FROM EXPANSION COHORTS IN PATIENTS WITH COLORECTAL CANCER AND EWING SARCOMADEMONSTRATE HIGH RESPONSE AND DISEASE CONTROL RATES IN DIFFICULT-TO-TREAT, HEAVILY PRETREATED PATIENTS MANAGEMENT TO HOST CONFERENCE CALL TODAY AT 1:30 P.M. PACIFIC TIME,TO REVIEW THE TOPLINE RESULTS AND ONGOING COHORTS SAN DIEGO , OCT. 23, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE REGISTRATIONAL CHONDRAGON STUDY (N= 206) INVESTIGATING OZEKIBART (INBRX-109) AS A SINGLE AGENT VERSUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC, UNRESECTABLE CHONDROSARCOMA.

INHIBRX BIOSCIENCES REPORTS POSITIVE TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND PROVIDES UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS

 EVENT TO BE WEBCAST LIVE ON THURSDAY, OCTOBER 23, 2025 AT 1:30 P.M. PT  SAN DIEGO , OCT. 22, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST PRESENTATION ON THURSDAY, OCTOBER 23, 2025 AT 1:30 P.M.

INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS

SAN DIEGO , AUG. 13, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025.FOLLOWING THE COMPLETION OF THE SALE OF INBRX-101 (THE "101 TRANSACTION") BY INHIBRX, INC. (THE "FORMER PARENT") TO SANOFI S.A.

INHIBRX REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO , MAY 14, 2025 /PRNEWSWIRE/ --INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025. FOLLOWING THE COMPLETION OF THE SALE OF INBRX-101 BY INHIBRX, INC. (THE "FORMER PARENT") TO SANOFI S.A.

INHIBRX REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO , APRIL 1, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY WITH TWO PROGRAMS IN CLINICAL-STAGE DEVELOPMENT, TODAY ANNOUNCED THE DEPARTURE OF DR. BRENDAN ECKELMAN, CO-FOUNDER AND CHIEF SCIENTIFIC OFFICER (CSO) AND THE APPOINTMENTS OF DR. CARLOS BAIS AND DAVID MATLY TO CSO AND PRESIDENT, RESPECTIVELY. DR. ECKELMAN LEAVES THE COMPANY TO ESTABLISH A NEWLY-FORMED PRIVATE BIOTECHNOLOGY COMPANY, WHERE HE WILL BE FOUNDER AND CHIEF EXECUTIVE OFFICER.

INHIBRX BIOSCIENCES ANNOUNCES DEPARTURE OF CSO AND APPOINTMENTS OF NEW CSO AND PRESIDENT

SAN DIEGO , MARCH 17, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY") TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2024. FOLLOWING THE COMPLETION OF THE SALE OF INBRX-101 BY INHIBRX, INC. (THE "FORMER PARENT") TO SANOFI S.A.

INHIBRX REPORTS FOURTH QUARTER AND FISCAL YEAR 2024 FINANCIAL RESULTS

SAN DIEGO , JAN. 21, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. (NASDAQ: INBX) ("INHIBRX" OR THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING THERAPEUTICS FOR ONCOLOGY AND RARE DISEASES, TODAY ANNOUNCED PRELIMINARY EFFICACY AND SAFETY DATA FROM THE PHASE 1 TRIAL OF OZEKIBART (INBRX-109) IN COMBINATION WITH FOLFIRI FOR THE TREATMENT OF ADVANCED OR METASTATIC, UNRESECTABLE COLORECTAL ADENOCARCINOMA (CRC). THESE RESULTS WERE PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL ANNUAL CANCERS SYMPOSIUM.

INHIBRX BIOSCIENCES ANNOUNCES PRELIMINARY DATA FROM THE PHASE 1 TRIAL OF OZEKIBART (INBRX-109) FOR THE TREATMENT OF COLORECTAL CANCER

SAN DIEGO , JAN. 13, 2025 /PRNEWSWIRE/ -- INHIBRX BIOSCIENCES, INC. ("INHIBRX" OR THE "COMPANY") (NASDAQ: INBX), A BIOPHARMACEUTICAL COMPANY WITH TWO PROGRAMS IN ONGOING CLINICAL TRIALS, TODAY ANNOUNCED IT ENTERED INTO A LOAN AND SECURITY AGREEMENT (THE "LSA") WITH OXFORD FINANCE LLC ("OXFORD", TOGETHER WITH CERTAIN OF ITS AFFILIATES PARTY THERETO, THE "LENDERS"), PURSUANT TO WHICH THE LENDERS PROVIDED A FIVE-YEAR TERM LOAN FACILITY FOR UP TO $150 MILLION (THE "CREDIT FACILITY"). "THIS ENABLES US STRATEGIC FLEXIBILITY POST DATA READOUTS EXPECTED LATER THIS YEAR FOR OUR INBRX-109 AND INBRX-106 PROGRAMS," SAID KELLY DECK, CHIEF FINANCIAL OFFICER OF INHIBRX.

Inhibrx, Inc.

INBX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Inhibrx, Inc.

INBX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

INBX